Blog
RSS FeedPosted by Michael Wonder on 26 Oct 2019
Dialogue with Chinese authorities on medicine regulation
25 October 2019 - The Deputy Commissioner of the Chinese National Medical Product Administration, Dr Chen Shifei, visited EMA on ...
Posted by Michael Wonder on 21 Oct 2019
China wants big pharma to bend the knee in new health care system
21 October 2019 - Less than five years ago, Chinese health care was a closed-off, low-quality system where the richest ...
Posted by Michael Wonder on 03 Oct 2019
Merck’s Keytruda (pembrolizumab) now approved as monotherapy in China for first-line treatment of certain patients with advanced non-small cell lung cancer (NSCLC) whose tumours express PD-L1
2 October 2019 - Keytruda is first anti-PD-1 therapy approved as monotherapy and in combination with chemotherapy in first-line setting for ...
Posted by Michael Wonder on 27 Sep 2019
Erbitux in combination with FOLFOX or FOLFIRI approved as first-line therapy for patients in China with RAS wild type metastatic colorectal cancer
27 September 2019 - Pivotal Phase III evidence shows significant improvements with Erbitux in combination with FOLFOX versus FOLFOX alone ...
Posted by Michael Wonder on 25 Sep 2019
China’s drug price cuts pressure Lipitor and other foreign pills
24 September 2019 - Government is changing the way it procures generic drugs. ...
Posted by Michael Wonder on 14 Sep 2019
U.S. officials worried about Chinese control of American drug supply
13 September 2019 - "Basically we've outsourced our entire industry to China," retired Brig. Gen. John Adams told NBC News. "That ...
Posted by Michael Wonder on 12 Sep 2019
China’s grip on pharmaceutical drugs is a national security issue
10 September 2019 - If you take a pill every day to treat high blood pressure or high cholesterol, you ...
Posted by Michael Wonder on 05 Sep 2019
Tagrisso approved in China as a first-line treatment for EGFR-mutated non-small cell lung cancer
4 September 2019 - In the Phase III FLAURA trial, Tagrisso significantly increased the time patients lived without disease progression ...
Posted by Michael Wonder on 02 Sep 2019
China expands drug bulk-buy program, puts pressure on pharma firms
2 September 2019 - China has expanded a pilot drug bulk-buying program to almost the entire country in an attempt ...
Posted by Michael Wonder on 27 Aug 2019
China eases rules on cheap drug imports to fight chronic diseases
27 August 2019 - China said it would reduce the penalties for the sale and import of unapproved drugs, effectively ...
Posted by Michael Wonder on 26 Aug 2019
China loosens curbs on small, unapproved drug imports
26 August 2019 - China said on Monday it was relaxing drug laws to give greater leniency to people who ...
Posted by Michael Wonder on 26 Aug 2019
China revises law to ensure drug safety
26 August 2019 - China's top legislature on Monday voted to adopt the revision to the drug administration law as ...
Posted by Michael Wonder on 24 Aug 2019
China vows to maintain stable drug prices
22 August 2019 - Chinese authorities vowed to take actions to make sure the drug prices are set reasonably by ...
Posted by Michael Wonder on 22 Aug 2019
Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease
22 August 2019 - China becomes the first country to approve roxadustat for all chronic kidney disease patients with anaemia ...
Posted by Michael Wonder on 20 Aug 2019
China adds 148 drugs to key insurance list
20 August 2019 - China on Tuesday added 148 drugs to its list of medicines covered by basic medical insurance ...